Goldman Sachs Group Inc Rocket Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 424,073 shares of RCKT stock, worth $5.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

424,073

Previous 695,908 39.06%

Holding current value

$5.53 Million

Previous $15 Million 47.72%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$17.6 - $25.88 $4.78 Million - $7.04 Million	-271,835 Reduced 39.06%	424,073 $7.83 Million
Q2 2024 Aug 13, 2024	BUY	$20.66 - $26.72 $5.48 Million - $7.08 Million	265,033 Added 61.51%	695,908 $15 Million
Q1 2024 May 15, 2024	SELL	$26.16 - $30.74 $4.28 Million - $5.03 Million	-163,790 Reduced 27.54%	430,875 $11.6 Million
Q4 2023 Feb 13, 2024	BUY	$16.78 - $31.94 $1.09 Million - $2.07 Million	64,946 Added 12.26%	594,665 $17.8 Million
Q3 2023 May 14, 2024	SELL	$15.07 - $24.05 $978,736 - $1.56 Million	-64,946 Reduced 10.92%	529,719 $10.9 Million
Q3 2023 Nov 14, 2023	SELL	$15.07 - $24.05 $13.7 Million - $21.9 Million	-911,191 Reduced 63.24%	529,719 $10.9 Million
Q2 2023 May 14, 2024	SELL	$16.59 - $23.6 $3.5 Million - $4.98 Million	-210,817 Reduced 12.76%	1,440,910 $28.6 Million
Q2 2023 Aug 14, 2023	SELL	$16.59 - $23.6 $3.5 Million - $4.98 Million	-210,817 Reduced 12.76%	1,440,910 $28.6 Million
Q1 2023 May 14, 2024	BUY	$15.79 - $22.6 $9.83 Million - $14.1 Million	622,563 Added 60.49%	1,651,727 $28.3 Million
Q1 2023 May 11, 2023	BUY	$15.79 - $22.6 $9.83 Million - $14.1 Million	622,563 Added 60.49%	1,651,727 $28.3 Million
Q4 2022 May 14, 2024	SELL	$15.5 - $22.76 $15.6 Million - $22.9 Million	-1,007,480 Reduced 49.47%	1,029,164 $20.1 Million
Q4 2022 Feb 13, 2023	SELL	$15.5 - $22.76 $15.6 Million - $22.9 Million	-1,007,480 Reduced 49.47%	1,029,164 $20.1 Million
Q3 2022 May 14, 2024	BUY	$12.37 - $18.41 $6.6 Million - $9.83 Million	533,749 Added 35.51%	2,036,644 $32.5 Million
Q3 2022 Nov 10, 2022	BUY	$12.37 - $18.41 $6.6 Million - $9.83 Million	533,749 Added 35.51%	2,036,644 $32.5 Million
Q2 2022 May 14, 2024	BUY	$7.96 - $16.64 $7.23 Million - $15.1 Million	908,230 Added 152.73%	1,502,895 $20.7 Million
Q2 2022 Aug 15, 2022	SELL	$7.96 - $16.64 $389,076 - $813,346	-48,879 Reduced 3.15%	1,502,895 $20.7 Million
Q1 2022 May 16, 2022	BUY	$13.16 - $23.68 $11.7 Million - $21 Million	886,919 Added 133.4%	1,551,774 $24.6 Million
Q4 2021 Feb 14, 2022	SELL	$21.52 - $36.02 $6.52 Million - $10.9 Million	-302,742 Reduced 31.29%	664,855 $14.5 Million
Q3 2021 Nov 10, 2021	BUY	$27.42 - $48.97 $26.5 Million - $47.4 Million	967,597 New	967,597 $28.9 Million

Others Institutions Holding RCKT

# of Institutions

209

Shares Held

93.2M

Call Options Held

319K

Put Options Held

70.3K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $987M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Rocket Pharmaceuticals, Inc. Transaction History